Background
Glioblastoma (GBM) is the most aggressive of all intracranial tumors. Despite multimodal treatment including surgical resection, chemotherapy and radiotherapy, the median survival is only 14.6 months [
1,
2]. Radiotherapy targets cancer cells by causing DNA damage and is a highly cost-effective treatment [
3]. However, DNA damage induced by radiation triggers a series of signaling cascades promoting cell survival, including DNA repair, cell cycle arrest, and autophagy, all of which mediate radioresistance and prevent further clinical efficacy [
4].
Autophagy is a lysosome-dependent degradation and cell survival process which represents a therapeutic target in cancer treatment due to its role in DNA damage [
5]. Several studies have shown that inhibiting autophagy could increase the radiosensitivity of tumor cells [
6‐
8]. Currently, multiple clinical trials have been initiated that combine conventional anti-cancer therapies with inhibition of autophagy [
9‐
11]. Previous studies have shown that Bafilomycin A1, a vacuolar H
+-ATPase inhibitor, increases DNA degradation and significantly increases survival after irradiation of MCF-7 (human breast adenocarcinoma), LoVo (human colon adenocarcinoma), and LNCaP (human prostate carcinoma) cells [
12]. However, due to the blood-brain-barrier (BBB), most autophagy inhibitors will not effectively benefit GBM patients. Therefore, identifying new autophagy inhibitors with improved pharmacokinetics for diseases in the central nervous system (CNS) is urgently needed.
Trifluoperazine (TFP) is a typical antipsychotic compound of the phenothiazine chemical class. It has been used in the treatment of schizophrenia for more than 50 years and relieves agitation in patients with behavioral problems, severe nausea and vomiting as well as severe anxiety [
13]. Recently, an increasing number of studies have found that TFP has potent anti-tumor effects in lung cancer, malignant peripheral nerve sheath tumors and leukemia [
14‐
16]. Here, we examined the responses of GBM cells to TFP in vitro and in vivo and show that TFP inhibits autophagy by interfering with lysosome acidification. Moreover, TFP treatment impairs DNA damage repair following radiotherapy, providing a rationale for combining TFP with radiation therapy in GBMs.
Methods
Cell lines
Human glioma cell lines U87 and U251 were purchased from the cell bank of the Chinese Academy of Sciences and were cultured in Dulbecco’s modified Eagle’s medium (ThermoFisher Scientific; Waltham, MA, USA) containing 10% fetal bovine serum (ThermoFisher Scientific), glutamine (4 mM), penicillin (10 U/mL), and streptomycin (100 mg/mL). Normal human astrocytes (NHA) were purchased from Lonza (Walkersville, MD, USA) and were cultured in Astrocyte Medium BulletKit (Lonza) according to the manufacturer’s instructions. P3 is a primary GBM cell line isolated from a patient biopsy. The P3 tumor has the following molecular characteristics (+ [Chr 7, Chr19, 20q], −[1q42-q43, Chr9, Chr10, 20p] --[PIK3R1, CDKN2A/B]. P3 cells were cultured in Neurobasal Medium (ThermoFisher Scientific) containing penicillin (10 U/mL), streptomycin (100 mg/mL), B27 supplement (20 μL/mL), FGF (20 ng/mL), EGF (20 ng/mL) and heparin (32 IE/mL).
Cell viability assay
The cytotoxic effect of TFP (Sigma; St. Louis, MO, USA) on the GBM cell lines, P3 and NHA cells was determined using the CCK-8 assay (Dojindo; Kumamoto, Japan). Cells were suspended in DMEM with 10% fetal bovine serum (FBS) or Neurobasal Medium (for P3) and seeded into 96-well, flat-bottomed plates (5 × 103 cells/well). After incubation overnight at 37 °C, cells were pretreated with PBS or TFP (0–30 μM). After 24 h or 48 h of culture, cells were incubated for an additional 2 h at 37 °C with 100 μL of serum-free DMEM or Neurobasal Medium (for P3 cells) containing 10 μL of CCK-8, and absorbance was measured at a wavelength of 450 nm using a microplate reader (BioRad; Hercules, CA, USA).
EdU proliferation assay
The tumor cells (2.5 × 104 cells/well) were seeded into 24-well, flat-bottomed plates. After 24 h, cells were treated with PBS, 5 and 10 μM of TFP for an additional 48 h in DMEM with 10% serum, and subsequently stained with EdU using the Apollo Detection Kit (Ribobio; Guangzhou, China) according to the manufacturer’s instructions. EdU positive cells were counted from at least 10 random fields by fluorescence microscopy (Leica DMi8; Leica Microsystems, Wetzlar, Germany).
Western blot analysis
After treatment of different doses of TFP, 100 nM bafilomycin A1, 2.5 μM rapamycin, 4 Gy radiation at a dose rate of 1.8 Gy/min using a linear accelerator (Primus Hi; Siemens Medical Instruments; Erlangen, Germany) or 5 μM TFP for 24 h before receiving one dose of 4 Gy, whole-cell protein extracts (20-50 mg) were prepared using a radioimmunoprecipitation assay buffer (RIPA; Thermo Fisher Scientific) supplemented with protease inhibitor cocktail (Cell Signaling Technology; Beverly, MA, USA). Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. Membranes were blocked with 5% skimmed milk in Tris-buffered saline containing 0.1% Tween-20, and subsequently incubated with primary and indicated secondary antibodies (Thermo Fisher Scientific). Proteins on western blots where visualized using the Chemiluminescent Reagents Kit (Millipore, Billerica, MA, USA). Chemiluminescent signals were detected with the ChemiDoc XRS+ (Bio-Rad, Hercules, CA, USA) and quantified using Image Lab 3.0 software (Bio-Rad). The following primary antibodies were used for western blotting: beta-tubulin, LC3BI/II, phospho-histone H2A.X (Ser139; also known as γ-H2A.X), P62 and survivin (Cell Signaling Technology; Beverly, MA, USA); GAPDH, BRCA1, BRCA2 and Rad51 were purchased from Santa Cruz (Dallas, TX, USA).
GFP-LC3 transient transfection
Cells were transiently transfected with the pSELECT-GFP-LC3 plasmid (Genepharma; Shanghai, China) using Lipofectamine 2000 reagent (ThermoFisher Scientific) according to the manufacturer’s instructions. After being treated with PBS or 10 μM TFP for 24 h, cells were observed using a Leica TCS SP5 Confocal Laser Scanning Microscope (Leica Microsystems) and GFP-LC3 puncta per cell was counted. Ten random fields were obtained per treatment group.
Transmission electron microscopy
Cells were fixed in 3% glutaraldehyde in PBS for 2 h, washed five times with 0.1 M cacodylate buffer, and post-fixed with 1% OsO4 in 0.1 M cacodylate buffer containing 0.1% CaCl2 for 1.5 h at 4 °C. Cells were dehydrated in graded alcohol series and embedded in epoxy resin. Ultrathin sections were cut and stained with uranyl acetate and lead citrate. Images were obtained using a JEM-1200EX II electron microscope (JEOL, Tokyo, Japan).
LysoTracker staining
Following treatment with PBS (control), 100 nM bafilomycin A1 and 10 μM TFP for 48 h, U251 and U87 cells were rinsed 3 times with fresh medium, and Lyso-Tracker Red (diluted in DMEM with 10% FBS; ThermoFisher Scientific) was added to a final concentration of 66 nM. Cells were incubated for 30 min at 37 °C and rinsed with phosphate-buffered saline (PBS). Nuclei were stained with 5 μg/ml Hoechst 33,342 (ThermoFisher Scientific), and live cells were observed using a Leica DMi8 fluorescence microscope.
Comet assay (single cell gel electrophoresis assay)
Comet assays were performed according to a previously described protocol [
17]. Briefly, after treatment with PBS, TFP, radiation or combination treatment, cells were thoroughly mixed with low melting point agarose solution. Radiation treatment was carried out with a single dose of 4 Gy at a dose rate of 1.8 Gy/min using a linear accelerator (Primus Hi). The cell suspension was spread on a Comet Slide (CometAssay® Kit, Trevigen; Gaithersburg, MD, USA) covered with 1.5% normal melting agarose. Slides were immersed in prepared lysis solution, treated with Tris-EDTA buffer (10 mM TrisCl, pH 7.5, 1 mM EDTA), and then placed horizontally on an electrophoresis tray filled with alkaline solution (300 mM NaOH, 1 mM EDTA). Electrophoresis was conducted at room temperature with an electrical field of 25 V and a current of 300 mA for 20 min. After electrophoresis, the slides were stained with GelRed (Biotium; Fremont, CA, USA). Slides were examined under fluorescence microscopy. Cells were analyzed using the Comet Assay Software Project (CASP). Olive tail moment (OTM) was used to quantify the extent of DNA damage.
Immunofluorescence
Immunofluorescence detection of γ-H2A.X foci was performed to monitor formation of DNA double strand breaks (DSBs). Cells cultured on coverslips were treated with PBS or 5 μM of TFP before receiving one dose of 4 Gy at a dose rate of 1.8 Gy/min using a linear accelerator (Primus Hi). At indicated time points (2, 6, 12 and 24 h), the cells were rinsed with PBS and then fixed in 4% paraformaldehyde before permeabilisation with 0.3% Triton X-100. After blocking with 5% BSA (Sigma), cells were incubated with diluted primary antibody for γ-H2A.X overnight at 4 °C, followed by staining with Fluorescein (FITC)-conjugated goat anti-rabbit IgG (ThermoFisher Scientific). Finally, the samples were mounted in mounting medium containing DAPI (ThermoFisher Scientific). Three random fields were examined at a magnification of ×63 by a Leica TCS SP5 Confocal Laser Scanning Microscope.
U251 and U87 cells (3 × 103 cells/well) were plated in six-well plates. The adherent cells were then treated with PBS or 5 μM TFP for 24 h before receiving one dose of 4 Gy at a dose rate of 1.8 Gy/min whereupon they were incubated for 14 days. Then colonies were washed with PBS, fixed in 4% paraformaldehyde, stained with 0.1% crystal violet and counted. Colonies consisting of more than 50 cells were counted as surviving colonies.
Apoptosis analysis
Apoptosis was measured by quantifying cleaved-caspase 3 and 7 activity using Cell Event Caspase 3/7 Green Detection Reagent (Life Technologies, Carlsbad, CA, USA). Cells were plated in 96-well plates with a density of 3000 cells per well and allowed to adhere. Thereafter, the cells were treated with PBS or 5 μM TFP for 24 h before receiving one dose of 4 Gy at a dose rate of 1.8 Gy/min in a linear accelerator (Primus Hi). Then the cells were inspected using an IncuCyte Zoom live cell imaging system (Essen BioScience, Ann Arbor, MI, USA).
Homologous recombination (HR) assay
An HR assay (Norgen Biotek, Thorold, ON, Canada) was performed on U251 and U87 cells according to manufacturer’s instructions. Briefly, at day 3 after TFP treatment, cells were transfected with a positive control plasmid or two HR dl plasmids (dl-1 and dl-2). After 24 h of transfection, DNA was isolated using the Wizard genomic DNA purification kit (Promega, Madison, WI, USA). qPCR was performed with the supplied primers using a Roche LightCycler 480 II (Roche Applied Science, Indianapolis, IN, USA).
Cathepsin B and L activity
Activity of cathepsin B and L in U251 and U87 cells was tested using a Fluorometric Assay Kit (Abcam, Cambridge, UK) according to the manufacturer instructions. Briefly, after treatment with PBS (control) or 5 μM TFP for 24 h, the cells were lysed and supernatants were incubated with cathepsin-B (Ac-RR-AFC) or L (AC-FR-AFC) substrates at 37 °C for 1.5 h. Then samples were measured on a fluorescent microplate reader at excitation/emission wavelength = 400/505 nm. After subtracting the background control (buffer) from sample readings, activity of cathepsin B and L was determined by comparing results from TFP treated cells with the level from controls.
Transfection of siRNA
U251 and U87 cells were transfected with siRNA twice at a 24-h interval with lipofectamine 2000. The final concentration of siRNAs was 50 nM. Sequences for the siRNAs used were the following: cathepsin L, 5′-GATGCACAACAGATTATACTT-3′; nontargeting siRNA controls, 5′-UUCUCCGAACGUGUCACGUTT-3′ (Genepharma). Western blot analysis was used to assess the downregulation of cathepsin L.
Intracranial implantation and drug therapy
All animal protocols were approved by the ethics committee at the Shandong University (Jinan, China) and conducted according to the national regulations in China. For implantations, nude mice were anesthetized with 4% chloral hydrate (300 mg/kg) and placed in a stereotactic frame. Using aseptic surgical procedures, an incision was made in the parietal scalp, and a small burr hole was drilled 2.5 mm lateral to the bregma. U251 and P3 cells (1 × 106 cells/mouse) were implanted 2.0 mm into the right striatum using a Hamilton syringe (Hamilton Co., Reno, NV, USA). Two weeks later, mice were randomly divided into four groups (6 mice/group). Groups 1 and 2 were injected intraperitoneally (IP) with PBS or TFP (1 mg/kg, 5 days/week). Group 3 was given three doses of localized irradiation (5 Gy) at days 15, 20, and 25 after implantation following IP injection of PBS. Group 4 was irradiated three times following IP injection of TFP. Mice were sacrificed when central nervous system symptoms (such as poor ambulation, lethargy, hunched posture) or weight loss > 20% body mass developed. The mice were anesthetized with chlorohydrate and perfused transcardially with 4% paraformaldehyde in PBS. Whole brains were removed, post-fixed overnight in 4% paraformaldehyde in PBS, coronally sectioned into 5 slices, and paraffin embedded. Tissue sections were cut (10 μm) and incubated with primary antibodies as indicated. The following primary antibodies were used for immunohistochemistry: Ki67 (Abcam); γ-H2A.X (Cell Signaling Technology), and Rad51 (Santa Cruz).
Statistical analysis
Unpaired T-tests were performed using SPSS software 13.0 (SPSS Inc., Chicago, IL). Results are presented as the mean ± SE. P-values <0.05 were considered statistically significant.
Discussion
Recent research has shown that autophagy has a cytoprotective effect during anticancer therapy with DNA-damaging agents. It has also been shown that autophagy inhibition can sensitize tumor cells to such agents [
8,
36]. In general, the cytoprotective function of autophagy appears to be linked to apoptosis inhibition through a cross-talk between autophagy and apoptosis regulatory pathways [
4]. Therefore, clinical trials have been initiated combining autophagy inhibitors with traditional radio-chemotherapy for the treatment of GBMs [
9‐
11]. However, due to a limited BBB penetration, many autophagy inhibitors do not reach effective concentrations within the brain, −or the dosage is so high that it causes serious side effects. Therefore, novel autophagy inhibitors that can effectively enter the brain are urgently needed.
Drug repurposing has gained increased attention since these drugs have documented safety profiles from clinical use. It is well known that established drugs may have other mechanisms of action beyond the purpose for which they were developed. Drug repositioning also overcome, to a large extent, problems related to laborious and expensive drug development processes [
37]. Furthermore, the development of many compounds runs into issues related to safety. Although known as an autophagy inducer [
38,
39], an increasing number of studies have illustrated that TFP shows therapeutic efficacy towards various neoplasms, such as lung cancer, malignant peripheral nerve sheath tumors, and leukemia [
14‐
16]. Here, we show that TFP inhibits GBM growth in vitro and in vivo. Mechanistically we show that TFP interrupts autophagy flux by inhibiting the acidification of lysosomes.
Radiation therapy combined with temozolomide (TMZ) treatment represents the standard treatment of care for GBM patients. However, therapeutic efficacy is significantly limited by the development of tumor resistance mechanisms, both towards radiation therapy and TMZ. Radioresistance can develop by multiple factors mediated by the tumor cells as well as by the microenvironment [
40]. DNA damage repair is an essential mechanism that is triggered in cells for maintaining genetic integrity, −in order to survive potentially lethal levels of DNA damage. Among all the factors involved in DNA damage repair, HR plays the most prominent role. Early studies have shown that multiple immortalized, tumor cell lines and primary tumor samples overexpress Rad51 [
41,
42]. These studies have implicated Rad51 in oncogenesis and indicate that tumor cells show extreme capabilities to repair DNA damage caused by chemotherapy and radiotherapy. In the present work, we show that TFP decreases the expression of the HR proteins Rad51, BRCA1 and BRCA2, followed by increased DNA damage. This indicates that HR efficiency is attenuated during TFP treatment.
In our study, we find that TFP impairs lysosome acidification. Lysosomal proteases, especially cathepsins play an important role in late stage of autophagy [
28,
32]. Some studies also demonstrate that cathepsin L contributes to the radioresistance of GBM cells [
34,
35]. We show here that the activity as well as protein levels of cathepsin L decreases significantly after TFP treatment. Moreover, western blot analysis shows that cathepsin L silencing increases P62 and γ-H2AX, whereas Rad51 is decreased. Also, knock-down of cathepsin L led to a decreased HR efficiency. These results suggested that TFP might achieve a radiosensitivity effect by down-regulating cathepsin L. Therefore, cathepsin L might be an important factor in the regulation of autophagy, DSBs, and DNA damage repair, which makes it an attractive target in the radiosensitization of GBM.
The BBB is a major impediment to the entry of many drugs into the brain, partly because drugs that are P-glycoprotein (P-gp) substrates are extruded from the brain by the BBB [
43]. Studies have shown that TFP inhibits the expression of P-gp [
44], which may lead to effective drug concentrations within the brain and also GBMs.
In addition, TFP is also indicated for use in agitation, and in patients with behavioral problems as well as severe anxiety, severe nausea and vomiting, which may improve patients’ symptoms after surgery and radiation therapy. Thus, TFP might provide GBM patients with a better life quality during treatment. Given the long clinical use of TFP in psychotic and non-psychotic patients since the late 1950s, we provide a strong rationale for using TFP for the treatment of GBM patients together with standard therapy.